Micro-cap diagnostics companies rarely make headlines, yet Abingdon Health (LSE:ABDX) has quietly delivered numbers that force a second look. In its half year to 31 December 2025, the company reported total revenues, including grant-funded income, of £4.5m — a 45% jump on £3.1m a year earlier. More strikingly, its full-year trading update on 29 July 2026 confirmed the group had achieved adjusted EBITDA profitability in the second half of the year to 30 June 2026.

The headline poses a fair question: is Abingdon approaching a profitability inflection? The evidence is encouraging but nuanced. Adjusted EBITDA profit in one half-year is not the same as sustained bottom-line profit, and the group still carries losses, thin margins and negative operating cash flow. This article examines what Abingdon does, why the shares are in focus, the financial picture, and the bull and bear arguments as of 12 August 2026.

What the Company Does

Abingdon Health is a UK-based international developer and manufacturer of rapid diagnostic tests, headquarter in York. Its core Business is lateral-flow contract development and Manufacturing (a lateral-flow CDMO): it takes a customer's assay concept and moves it through development, validation, regulatory support and Volume manufacture. Lateral-flow tests are the low-cost, rapid-result format familiar from pregnancy and Covid-19 tests, and are used across human health, animal health, food, environmental and industrial markets.

The group came to wider notice during the Pandemic through Covid-19 antibody testing, but its strategy since has been to build a diversified pipeline of commercial CDMO contracts rather than depend on any single product. It has invested in capacity through Abingdon Health USA and its Abingdon Analytical laboratory, serving customers on both sides of the Atlantic. Revenue mixes contract development (R&D) fees, higher-volume manufacturing and some grant income — in effect making Abingdon the engine behind other companies' diagnostics, a model that can scale as early-stage programmes mature into recurring work.

Why the Stock Is in Focus

The catalyst is the combination of accelerating revenue and a first crossing into adjusted EBITDA profit. Second-half revenues rose 63% versus the first half, driven by growth in Contract Development (R&D) revenues — and that strength is what tipped the group into adjusted EBITDA profitability for the period.

For a company that has spent years as a cash-consuming AIM small-cap, any evidence that the model can generate positive Earnings before Depreciation and non-cash items is material. The market is testing the durability of that shift: was the second half a one-off boosted by R&D timing, or the start of a structurally more profitable trajectory as CDMO contracts scale into FY27?

Latest Financial Picture

For the half year to 31 December 2025, Abingdon reported total revenues of £4.5m including grant income (up 45%), with reported revenue of £4.2m (up 37%). The loss before taxation narrowed to £2.3m from £2.6m, and the adjusted EBITDA loss to £1.7m from £1.9m. Cash stood at £3.7m, helped by £3.2m of net proceeds from an October 2025 fundraising, against £1.9m at 30 June 2025.

For the full year to 30 June 2026, the 29 July 2026 trading update reported total revenue of £11.3m including grant income, up 31% on FY25's £8.6m, with H2 63% higher than H1. Crucially, the group achieved adjusted EBITDA profitability in H2 and closed the year with cash of £2.9m, up from £1.9m. Management expressed confidence in further FY27 growth, supported by secured CDMO contracts and international expansion.

One caveat deserves emphasis. In its earlier interim update the company had guided towards full-year revenue of around £12.6m (including £0.4m grant income); the £11.3m outcome fell short, with roughly £0.5m of reader-unit sales slipping into August and a Find Out From Home contract deferred into FY27. The Top Line thus landed below the earlier target even as growth and half-year profitability improved.

The Bull Case

The strongest bull argument is operational leverage. Abingdon has shown that, at a higher revenue run-rate, its CDMO model can turn adjusted EBITDA-positive — a threshold it had long chased. If FY27 delivers the growth management expects from secured contracts and its expanding US footprint, the group could move towards sustained profitability rather than periodic dilutive cash calls.

Growth is also broadening: contract development revenues rose sharply, the company reports visibility over a reasonable portion of FY27 revenue, and cash rose to £2.9m. For a diagnostics micro-cap, durable Demand plus a credible route to profit is the re-rating ingredient bulls are watching.

The Bear Case

The bear case starts with the fact that Abingdon remains loss-making, with a first-half pre-tax loss of £2.3m, declining gross margins and negative operating cash flow. Adjusted EBITDA profit strips out depreciation, share-based payments and certain non-recurring items — useful, but not the same as cash-generative net profit.

The FY26 revenue outcome of £11.3m also undershot the earlier £12.6m signpost — a reminder that contract timing can slip and a small customer base makes revenue lumpy. With cash of £2.9m and a history of Equity raises, dilution risk cannot be dismissed if growth stalls. As a nano-cap on AIM, the shares can be Illiquid and volatile, and valuation is hard to anchor given the absence of earnings and dividends.

What Could Move the Stock Next?

The most immediate scheduled catalyst is the full audited results for the year to 30 June 2026, which the company expects to publish in early October 2026. Those accounts will show whether reported gross margins, cash flow and the statutory loss corroborate the encouraging adjusted EBITDA narrative.

Beyond that, investors will watch for new CDMO contract wins, the deferred Find Out From Home programme and August reader-unit sales, and evidence that the US and analytical operations are converting into revenue. Any commentary confirming — or diluting — the outlook for further FY27 growth would be the key swing factor.

Outlook

Is Abingdon Health approaching a profitability inflection? On the verifiable evidence, it has taken a real step towards one: 45% first-half revenue growth and adjusted EBITDA profitability in H2 FY26 are genuine milestones for a company long defined by losses. But the inflection is not complete. The group is still loss-making at the pre-tax line, gross margins have softened, Operating Cash Flow is negative, and full-year revenue landed below the earlier £12.6m target.

The debate therefore hinges on durability. If FY27 delivers the further growth management anticipates and the second-half profitability proves repeatable, the case for a re-rating strengthens; if contract timing slips again, dilution and Volatility remain live risks. The October full-year results should offer the first hard test of which path Abingdon is on.